Stockings E, et al. - For the first time, researchers performed a review assessing evidence for the efficacy of cannabinoids in chronic noncancer pain (CNCP) and addressing gaps in the literature by considering differences in outcomes based on cannabinoid type and specific CNCP condition, including all study designs, and following Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) guidelines. For this purpose, they searched MEDLINE, Embase, PsycINFO, CENTRAL, and clinicaltrials.gov in July 2017. As per outcomes, cannabinoids do not seem to be highly efficacious therapies for CNCP. They identified moderate- to high-grade evidence that supports using nabiximols to attain modest pain reductions as adjunctive therapy in multiple sclerosis-related pain. No significant impacts on physical or emotional functioning, and low-quality evidence of improved sleep and patient global impression of change were identified.